Clinical Study

Otsuka Tolvaptan Open Label Rollover Study For Adpkd

Posted Date: May 15, 2019

  • Investigator: Shashi Kant
  • Type of Study: Drug

Tolvaptan is being studied as a possible treatment for autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a disease that causes kidney cysts (cysts are like fluid-filled balloons), worsening kidney function, blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infe

Criteria:

Inclusion: Previous Participation In Otsuka 156-13-210 Double Blind Study, Egfr >= 20 Exclusion: He

Keywords:

Kidney Disease, Adpkd, Cysts, Nephrology

For More Information:

Karen Case, Ccrp
513-559-3367
karen.case@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.